Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 6/20 | 0.52 |
| ▸ | LTA4H | P09960 | 4/20 | 0.51 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.51 |
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.45 |
| ▸ | UBE2N | P61088 | 1/20 | 0.45 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.45 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.44 |
| ▸ | HRH1 | P35367 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7926791 | 0.90 | ESR1 (0.58) | ESR1LTA4HESR2 | |
| SCHEMBL5486149 | 0.87 | LTA4H (0.52) | ESR1LTA4HESR2KCNH2MCHR1 | |
| SCHEMBL7458538 | 0.86 | LTA4H (0.53) | ESR1LTA4HESR2KCNH2MCHR1 | |
| SCHEMBL7930070 | 0.85 | ESR1 (0.51) | ESR1LTA4HESR2 | |
| SCHEMBL10001885 | 0.81 | ESR1 (0.51) | ESR1ESR2 | |
| SCHEMBL8015505 | 0.78 | LTA4H (0.52) | LTA4HHRH3KCNH2ITGA4MCHR1 | |
| SCHEMBL8018905 | 0.77 | LTA4H (0.53) | LTA4HHRH3ITGA4MCHR1 | |
| SCHEMBL11551829 | 0.77 | LTA4H (0.60) | ESR1LTA4HESR2 | |
| SCHEMBL11550799 | 0.77 | LTA4H (0.60) | ESR1LTA4HESR2 | |
| SCHEMBL7772126 | 0.76 | LTA4H (0.60) | ESR1LTA4HESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0729956-B1 | Benzothiophene compounds, intermediates, compositions, and methods | LILLY CO ELI (US) | 2001-10-31 | — | — | EP | disclosed |
| EP-1113013-A1 | Benzothiophene compounds, intermediates, compositions and methods | Eli Lilly & Company (US) | 2001-07-04 | — | — | EP | disclosed |
| US-6197790-B1 | OSTEOPOROSIS | ELI LILLY AND COMPANY | 2001-03-06 | — | — | US | disclosed |
| US-6030986-A | POST-MENOPAUSAL SYNDROME, UTERINE FIBROID DISEASE, ENDOMETRIOSIS, AND AORTAL SMOOTH MUSCLE CELL PROLIFERATION; ESTROGEN INDUCED UTERINE CANCER; OSTEOPOROSIS; RESTENOSIS; CARDIOVASCULAR DISORDERS | ELI LILLY AND COMPANY (US) | 2000-02-29 | — | — | US | disclosed |
| US-5998441-A | ANTICHOLESTEROL AGENT; MIXTURE WITH ESTROGEN | ELI LILLY AND COMPANY (US) | 1999-12-07 | — | — | US | disclosed |
| US-5986109-A | UROGENITAL DISORDERS, CARDIOVASCULAR DISORDERS AND ANTICARCINOGENIC AGENTS | ELI LILLY AND COMPANY (US) | 1999-11-16 | — | — | US | disclosed |
| US-5985898-A | INHIBITING HYPERLIPIDEMIA RESULTED FROM ESTROGEN DEFICIENCY DISEASE, REDUCING SERUM CHOLESTEROL, | ELI LILLY AND COMPANY (US) | 1999-11-16 | — | — | US | disclosed |
| US-5981765-A | FOR TREATMENT OF POST-MENOPAUSAL SYNDROME INCLUDING OSTEOPOROSIS, CARDIOVASCULAR EFFECTS SUCH AS HYPERLIPIDEMIA, AND ESTROGEN-DEPENDENT CANCER, PARTICULARLY BREAST AND UTERINE CANCER | ELI LILLY AND COMPANY (US) | 1999-11-09 | — | — | US | disclosed |
| US-5977093-A | INHIBITING ESTROGEN-DEPENDENT CANCER | ELI LILLY AND COMPANY (US) | 1999-11-02 | — | — | US | disclosed |
| US-5969142-A | OXIDIZING SULFUR ATOM OF SUBSTITUTED BENZOTHIOPHENE, REACTING PRODUCT WITH NUCLEOPHILIC GROUP, REDUCING PRODUCT TO DESIRED COMPOUND | ELI LILLY AND COMPANY (US) | 1999-10-19 | — | — | US | disclosed |
| EP-0729956-A1 | Benzothiophene compounds, intermediates, compositions, and methods | ELI LILLY AND COMPANY (US) | 1996-09-04 | — | — | EP | disclosed |